Filing Flows

Filing Flows › ANI Pharmaceuticals (ANIP) › Next earnings date

ANI Pharmaceuticals (ANIP) earnings: beat the estimate

ANI Pharmaceuticals (ANIP) reported on Nov 5, 2026 and beat the EPS estimate: $2.70 against $2.18 (+23.8%). Revenue was $291M for Q3 2026, +28% year over year. The stock moved -4.1% on the report. It beat the EPS estimate in 100% of the quarters on record.

Last result+23.8% vs estimate
Beat rate100%

The last report

ANI Pharmaceuticals reported revenue of $291M for the third quarter 2026 (+28% Y/Y), net earnings $35.1M: Rare Disease and Brands total net revenues $182M, Generics and Other total net revenues $108M. How it makes money → · Every quarter →

ANI Pharmaceuticals: EPS against the estimate, last 5 reportsANI Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$1.77$2.04Nov 25$1.98$2.33Feb 26$1.30$2.05May 26$2.04$2.21Aug 26$2.18$2.70Nov 26
Latest (Nov 26): Estimate $2.18, Reported $2.70.
ANIP: the stock's move on each reportANIP: the stock's move on each reportNov 5, 2026-4.1%Aug 7, 2026-8.3%May 8, 2026-6.2%Feb 27, 2026-2.5%Nov 7, 2025-1.4%

ANI Pharmaceuticals' latest quarter

ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.

Questions

Did ANI Pharmaceuticals beat earnings?

ANI Pharmaceuticals (ANIP) reported on Nov 5, 2026 and beat the EPS estimate: $2.70 against $2.18 (+23.8%).

When does ANIP report earnings?

The next date is not set yet.

Does ANI Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.